PRE News and Press, Prenetics Global Limited From 01/11/23

3 Ways That Penny Stocks Can Make You Money in 2023 Penny stocks can also be a great way to make money if done correctly. Before you invest in a penny stock, it is important to do research into the company and understand how their stock works. This means understanding the risks associated wit...

Shares of Prenetics Global Limited (NASDAQ: PRE) were skyrocketing 27.8% higher as of 11:12 a.m. ET on Tuesday. The huge gain came after the company announced that the U.S. Food and Drug Administration (FDA) cleared ACT Genomics' ACTOnco comprehensive genomic profiling test for solid ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com We’re starting off the day with an overview of the biggest pre-market stock movers for Tuesday! Moving stocks this morning are acquisition deals, clinical trial data, a failed...

Prenetics Global ( NASDAQ: PRE ) said ACT Genomics received clearance from the U.S. Food and Drug Administration (FDA) for ACTOnco, the company's genomic profiling test for solid tumors. Prenetics noted that it had recently completed a majority stake acquisition of ACT Genomics. ...

Prenetics has completed the majority stake acquisition of ACT Genomics to spearhead its entry into to the US$80+ billion global precision oncology market FDA market authorization advances personalized cancer care in Asia Clearance sets the stage for continued R&D investment into early...

Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic profiling onto a single platform Cancer genomics testing is now standard practice for cancer care and has shown to be highly successful such as Foundation One (acquired by Roche), Grail ...

LONDON and HONG KONG, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced that its board of directors has authorized a share repurchase program, and ...

Prenetics Global press release ( NASDAQ: PRE ): Q3 GAAP EPS of -$0.21 misses by $0.08 . Revenue of $79.68M (+54.1% Y/Y) beats by $13.1M . For further details see: Prenetics Global GAAP EPS of -$0.21 misses by $0.08, revenue of $79.68M beats by $13.1M

LONDON and HONG KONG, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced its unaudited financial results for the third quarter ended September...

Prenetics Global press release ( NASDAQ: PRE ): Q2 GAAP EPS of -$2.91. Revenue of $51.72M (-34.5% Y/Y). Adjusted EBITDA  of $6.5M Raises full year adjusted EBITDA guidance to the range of US$35 million to US$45 million, with corresponding full year revenue gui...